Hepatocellular carcinoma is one of the most frequent malignant tumors worldwide: Portal
vein tumor thrombosis (PVTT) occurs in about 35%-50% of patients and represents a strong …

Simple Summary Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …

Portal vein tumor thrombus (PVTT) is strongly correlated to a poor prognosis for patients with
hepatocellular carcinoma (HCC). In this study, we uncovered a causative link between …

肝癌是病死率最高的恶性肿瘤之一. 我国每年约有38.3 万人死于肝癌, 占全球肝癌死亡病例数的
51%, 严峻的形势给我国的社会和医疗带来了沉重的负担. 不断增加的科研经费投入为我国肝癌 …

Post-resection recurrence remains an intractable problem in hepatocellular carcinoma
(HCC) management. Natural killer (NK) cell infusion is considered as a promising cancer …

As one of the typical adoptive cell transfer modality, cytokine-induced killer cell (CIK)-
mediated immunotherapy exhibits promising applications in cancer treatment. However, the …

In western countries, hepatocellular carcinoma (HCC) is a major reason for orthotopic liver
transplantation (OLT) with estimated recurrence rates between 15% and 20%. This selective …

Purpose: The overexpression of hypoxia-inducible factor 1α (HIF-1α) is a common finding in
hepatocellular carcinoma (HCC), and it leads to angiogenesis and poor prognosis …

Background The evidence of combining sorafenib with transarterial chemoembolization
(TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient …

Surgery remains to be the mainstay of treatment for hepatocellular carcinoma (HCC).
Nonetheless, its therapeutic efficacy is significantly impaired by postoperative recurrence …